NCT02922764: A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients will not be eligible for the expansion cohort
Exclusions: Known active or suspected brain or leptomeningeal metastases- see trial for details

Comments are closed.

Up ↑